What 9 Analyst Ratings Have To Say About NovoCure
Portfolio Pulse from Benzinga Insights
Over the last quarter, NovoCure (NASDAQ:NVCR) has received a mix of bullish, somewhat bullish, and indifferent ratings from analysts. The average 12-month price target for the company is $77.0, with a high of $115.00 and a low of $33.00. This average price target has increased by 4.76% over the past month.
August 04, 2023 | 3:46 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
NovoCure has received mixed analyst ratings over the last quarter, with an average 12-month price target of $77.0. This target has increased by 4.76% over the past month.
The mixed analyst ratings indicate uncertainty about the company's future performance. However, the increase in the average price target over the past month suggests a positive outlook. This could potentially impact the stock price, but the extent of the impact is uncertain due to the mixed ratings.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100